| |
|
Do investors value the FDA orphan drug designation?
Orphanet Journal of Rare Diseases201712:114
DOI: 10.1186/s13023-017-0665-6
© The Author(s). 2017
Received: 21 February 2017
Accepted: 9 June 2017
Published: 19 June 2017
Abstract
Background
The Orphan Drug Act is an important piece of legislation that uses financial incentives to encourage the development of drugs that treat rare diseases. This analysis studies the effects of a portion of the Orphan Drug Act, the orphan drug designation. Specifically, it studies the value that investors place on the orphan drug designation, by investigating how investors react to companies’ announcing that their product has received the designation.
Results
The results, on average, show that the stock price of a company increases by 3.36% after the announcement of the designation, increasing the value of the company. The results are more pronounced for oncology drugs, and drugs being developed by the smallest companies.
Conclusion
The orphan designation appears to be successful at generating positive value for companies, as seen by the positive and significant average increases in stock price.
No hay comentarios:
Publicar un comentario